These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 27692637)
1. A Review of Ferric Pyrophosphate Citrate (Triferic) Use in Hemodialysis Patients. Albright T; Al-Makki A; Kalakeche R; Shepler B Clin Ther; 2016 Oct; 38(10):2318-2323. PubMed ID: 27692637 [TBL] [Abstract][Full Text] [Related]
2. Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Fishbane SN; Singh AK; Cournoyer SH; Jindal KK; Fanti P; Guss CD; Lin VH; Pratt RD; Gupta A Nephrol Dial Transplant; 2015 Dec; 30(12):2019-26. PubMed ID: 26175145 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers. Pratt RD; Swinkels DW; Ikizler TA; Gupta A J Clin Pharmacol; 2017 Mar; 57(3):312-320. PubMed ID: 27557937 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis. Pratt RD; Grimberg S; Zaritsky JJ; Warady BA Pediatr Nephrol; 2018 Nov; 33(11):2151-2159. PubMed ID: 30003313 [TBL] [Abstract][Full Text] [Related]
5. Ferric pyrophosphate citrate for parenteral administration of maintenance iron: structure, mechanism of action, clinical efficacy and safety. Fishbane S; Ganz T; Pratt RD Curr Med Res Opin; 2022 Aug; 38(8):1417-1429. PubMed ID: 35726771 [TBL] [Abstract][Full Text] [Related]
6. Ferric Pyrophosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialysis. Shah HH; Hazzan AD; Fishbane S Semin Nephrol; 2016 Mar; 36(2):124-9. PubMed ID: 27236134 [TBL] [Abstract][Full Text] [Related]
7. Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis. Fishbane S; Shah HH Hemodial Int; 2017 Jun; 21 Suppl 1():S104-S109. PubMed ID: 28371161 [TBL] [Abstract][Full Text] [Related]
8. New Options for Iron Supplementation in Maintenance Hemodialysis Patients. Vaziri ND; Kalantar-Zadeh K; Wish JB Am J Kidney Dis; 2016 Mar; 67(3):367-75. PubMed ID: 26616335 [TBL] [Abstract][Full Text] [Related]
9. Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Gupta A; Lin V; Guss C; Pratt R; Ikizler TA; Besarab A Kidney Int; 2015 Nov; 88(5):1187-94. PubMed ID: 26154926 [TBL] [Abstract][Full Text] [Related]
10. A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis. Block GA; Mizani MR; Broumand V; Newby FD; Erinle A; Arias C; Block M; Brillhart S; Leppink A; Danese M; Dittrich M Am J Nephrol; 2024; 55(5):520-528. PubMed ID: 38972306 [TBL] [Abstract][Full Text] [Related]
11. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR; J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740 [TBL] [Abstract][Full Text] [Related]
12. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Gupta A; Amin NB; Besarab A; Vogel SE; Divine GW; Yee J; Anandan JV Kidney Int; 1999 May; 55(5):1891-8. PubMed ID: 10231452 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease. Gan L; Xie P; Tan Y; Wei G; Yuan X; Lu Z; Pratt R; Zhou Y; Hui AM; Li K; Fang Y; Zuo L Drugs R D; 2022 Jun; 22(2):119-129. PubMed ID: 35380419 [TBL] [Abstract][Full Text] [Related]
14. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients. Nguyen TV Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125 [TBL] [Abstract][Full Text] [Related]
15. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection]. Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257 [TBL] [Abstract][Full Text] [Related]
16. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. Toblli JE; Di Gennaro F PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811 [TBL] [Abstract][Full Text] [Related]
17. The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis . Umanath K; Greco B; Jalal DI; McFadden M; Sika M; Koury MJ; Niecestro R; Hunsicker LG; Greene T; Lewis JB; Dwyer JP Clin Nephrol; 2017 Mar; 87 (2017)(3):124-133. PubMed ID: 28128726 [TBL] [Abstract][Full Text] [Related]
18. Triferic for iron replacement. Med Lett Drugs Ther; 2017 Mar; 59(1517):55-56. PubMed ID: 28323812 [No Abstract] [Full Text] [Related]
19. Oral Low-Dose Ferric Citrate Is a Useful Iron Source for Hyperphosphatemic Hemodialysis Patients: A Case Series. Tanemoto M; Ishimoto Y; Saito H Blood Purif; 2017; 43(1-3):97-100. PubMed ID: 27951582 [TBL] [Abstract][Full Text] [Related]
20. [Iron replacement in hemodialysis patients with a normal serum ferritin level]. Riedel MK; Morgenstern T Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]